سعر سكيزولازين 10مجم 30 قرص 2024

Schisolazine 10 mg 30 orodispersible tablets: olanzapine 10 mg orodispersible tablets, pack of 30, by Pharco (Egypt); an atypical antipsychotic.

• Schizophrenia (adults and adolescents 13-17 years)Population: Adults; adolescents 13-17 yearsDailyMed (U.S. National Library of Medicine)
• Bipolar I disorder: acute treatment of manic or mixed episodes and maintenance treatment (monotherapy)Population: Adults; adolescents 13-17 years (acute)DailyMed (U.S. National Library of Medicine)
• Bipolar I disorder: manic or mixed episodes, as an adjunct to lithium or valproatePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in adults with schizophrenia (>=5% and at least twice placebo): postural hypotension, constipation, weight gain, dizziness, personality disorder (non-aggressive objectionable behaviour), akathisia. In adult bipolar mania: asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Adolescents (schizophrenia or bipolar mania): sedation, weight increased, headache, increased appetite, dizziness, abdominal pain, pain in extremity, fatigue, dry mouth.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None with olanzapine monotherapy (US label). When combined with fluoxetine, lithium or valproate, the contraindications of those products apply.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: elderly patients with dementia-related psychosis treated with antipsychotics have an increased risk of death; olanzapine is not approved for dementia-related psychosis (higher incidence of cerebrovascular adverse events was also seen).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Metabolic changes: hyperglycemia (sometimes extreme, with ketoacidosis, hyperosmolar coma or death), dyslipidemia and weight gain; monitor glucose, lipids and weight.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Neuroleptic malignant syndrome and DRESS (drug reaction with eosinophilia and systemic symptoms) have been reported; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Fluvoxamine (CYP1A2 inhibitor)Increases olanzapine exposure (mean AUC +52% in female non-smokers, +108% in male smokers); consider lower olanzapine doses.DailyMed (U.S. National Library of Medicine)
• Carbamazepine (CYP1A2 inducer)Increases olanzapine clearance.DailyMed (U.S. National Library of Medicine)
• Alcohol, diazepam and other CNS-acting drugsCaution: additive CNS effects; alcohol and diazepam may potentiate orthostatic hypotension.DailyMed (U.S. National Library of Medicine)

• Published epidemiologic data have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; untreated schizophrenia or bipolar I disorder also carries maternal risk. A US pregnancy exposure registry for atypical antipsychotics exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Olanzapine is present in human milk; excess sedation, irritability, poor feeding and extrapyramidal symptoms have been reported in breastfed infants. Weigh the benefits of breastfeeding against the mother's clinical need and monitor exposed infants.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Olanzapine: Antagonist at serotonin 5-HT2A/2C and dopamine D1–D5 receptors, with affinity also for muscarinic, histamine H1 and alpha-1 adrenergic receptors.